Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with [99mTc]-TRODAT-1 and a meta-analysis

Schizophrenia Bulletin

Volumn 39, Issue 2, 2013, Pages 378-386

  Chen, Kao Chin ^a,b,c,d   Yang, Yen Kuang ^a,b,c   Howes, Oliver ^d   Hui Lee, I ^a,b,c   Landau, Sabine ^d   Yeh, Tzung Lieh ^a,b,c   Chiu, Nan Tsing ^a   Chen, Po See ^a,b,c   Lu, Ru Band ^a,b,c   David, Anthony S ^d   Bramon, Elvira ^d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

dopamine; dopamine transporter; drug naive schizophrenia; meta analysis; single photon emission tomography; TRODAT

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG PROTEIN BINDING; FEMALE; HALLUCINATION; HUMAN; MALE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE SYNDROME; PRIORITY JOURNAL; RIGHT HEMISPHERE; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; SYSTEMATIC REVIEW; TAIWAN;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SCHIZOPHRENIA; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 84874509464     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr163     Document Type: Article

References (39)

1. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717-719.
2. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549-562.
3. Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull. 2011;37:108-117.
4. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009;15:2550-2559.
5. Howes OD, Montgomery AJ, Asselin M-C, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20.
6. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423-451. (Pubitemid 30164887)
7. Guo N, Guo W, Kralikova M, et al. Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology. 2010;35:806-817.
8. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56-72. (Pubitemid 29296818)
9. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231-239.
10. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97:8104-8109. (Pubitemid 30460780)
11. Laakso A, Bergman J, Haaparanta M, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res. 2001;52:115-120. (Pubitemid 32947054)
12. Mateos JJ, Lomena F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl). 2007;191:805-811. (Pubitemid 46355894)
13. Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res. 2003;65:39-46.
14. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry. 2004;161:1496-1498. (Pubitemid 38989108)
15. Schmitt GJ, la Fougere C, Dresel S, et al. Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naive schizophrenic patients. Schizophr Res. 2008;101:133-141.
16. Sjoholm H, Bratlid T, Sundsfjord J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl). 2004;173:27-31. (Pubitemid 38591143)
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33; quiz 34-57. (Pubitemid 29001829)
18. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab. 1990;10:458-466. (Pubitemid 20209192)
19. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-642.
20. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207-213. (Pubitemid 47618638)
21. Guy W. ECDEU Assessment for Psychopharmacology. Revised ed. Washington, DC: US Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
22. Hopper K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. Schizophr Bull. 2000;26:835-846.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
24. Kuikka JT, Tiihonen J, Karhu J, Bergstrom KA, Rasanen P. Fractal analysis of striatal dopamine re-uptake sites. Eur J Nucl Med. 1997;24:1085-1090. (Pubitemid 27435013)
25. Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812-1817. (Pubitemid 29523574)
26. Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD. Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med. 2007;32:452-455. (Pubitemid 46791464)
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed.Hillsdale,NJ: Lawrence Erlbaum Associates, Inc.; 1988.
28. Schmitt GJ, Meisenzahl EM, Frodl T, et al. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]-TRODAT-1. J Psychopharmacol. 2005;19:488-493. (Pubitemid 41392303)
29. Schmitt GJ, Frodl T, Dresel S, et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2006;256:115-121.
30. Chou Y-H, Huang W-S, Hsu J-W, Lee S-M, Yang A-S, Yang K-C. Simultaneous measurement of dopamine transporters and D2/D3 receptors in drug na?̈ve schizophrenic patients. Clin Psychopharmacol Neurosci. 2010;8:97-104.
31. Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry. 2000;47:371-379. (Pubitemid 30110609)
32. Dresel SH, Kung MP, Huang X, et al. In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999;26:342-347. (Pubitemid 29176444)
33. Inoue M, Katsumi Y, Hayashi T, et al. Sensory stimulation accelerates dopamine release in the basal ganglia. Brain Res. 2004;1026:179-184. (Pubitemid 39361546)
34. Wang GJ, Volkow ND, Levy AV, et al. MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comput Assist Tomogr. 1996;20:423-428. (Pubitemid 26142298)
35. BannonMJ,Michelhaugh SK,Wang J, Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol. 2001;11:449-455. (Pubitemid 33026519)
36. Fernagut PO, Li Q, Dovero S, et al. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One. 2010;5:e14053.
37. Moody CA, Granneman JG, Bannon MJ. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett. 1996;217:55-57. (Pubitemid 26342792)
38. Faraone SV, Chen WJ, Goldstein JM, Tsuang MT. Gender differences in age at onset of schizophrenia. Br J Psychiatry. 1994;164:625-629. (Pubitemid 24161260)
39. Chen PS, Yang YK, Lee YS, et al. Correlation between different memory systems and striatal dopamine D2/D3 receptor density: a single photon emission computed tomography study. Psychol Med. 2005;35:197-204. (Pubitemid 40259912)